sah

SAH (SAH (S-Adenosylhomocysteine)) is an inhibitor for the METTL3-METTL14 heterodimer complex (METTL3-14, IC50: 0.9 μM).

CN-SAH is a potent and selective inhibitor of DOT1L.

EZH2/EPP interaction inhibitor (Kd = 320 nM). Suppresses EZH2 expression and H3K27 trimethylation by PCR2 complex. Arrests proliferation and induces monocyte to macrophage differentiation of MLL-AF9 leukemia cell line.

KRas/son of sevenless 1 (SOS1) interaction inhibitor. Binds within nucleotide binding pocket of KRas (Kd values are 106 - 176 nM for wild type KRas and various KRas mutants). Inhibits nucleotide binding to KRas in a concentration dependent manner. Display

HLY78 (4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine) targets the DIX domain of Axin, is an activator of the Wnt/β-catenin signaling pathway and can enhance Axin-LRP6 binding to promote Wnt signaling.

FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding.

FIDAS-5 is an orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. It can effectively compete with S-adenosylmethionine for MAT2A binding and has anticancer effects.

SIBA (5'-Deoxy-5'-isobutylthioadenosine) is a synthetic analogue of SAH, acts as an inhibitor of S-adenosylmethionine-mediated transmethylation. SIBA can interfere with a variety of enzymatic activities in vitro, such as SAH hydrolase, methylthioadenosine phosphorylase and cAMP phosphodiesterase. SIBA reversibly blocks the multiplication of herpes simplex type 1 virus (HSV)

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM).

SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity ( EC 50 =106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS [1] .

Docosahexaenoic Acid (DHA) is an essential omega-3 fatty acid prevalent in the brain and retina.

1-Docosahexaenoyl-sn-glycero-3-phosphocholine, an ester product, is a phospholipid containing DHA (docosahexaenoic acid), often used in biomedical research as an important source of omega-3 fatty acids.

Palmitoyldocosahexaenoyl phosphatidylcholine is a polyunsaturated fatty acid that mimics special cell membrane structural domain lipids.

Docosahexaenoic Acid methyl ester (all cis-DHA methyl ester) is a methylated docosahexaenoic acid analog that can be inserted into membrane phospholipids without being oxidized or hydrolyzed.

SAHA chloroalkane T1 is a novel compound formed by combining Vorinostat (SAHA) with a chloroalkane capture tag, referred to as T1. This innovative approach involves tethering the SAHA molecule with the T1 tag, resulting in the formation of SAHA chloroalkane T1.

1-1(Z)-Octadecenyl-2-docosahexaenoyl-sn-glycero-3-PE (18:0p/22:6-PE) is a lipid identified in rat brain tissue using mass spectrometry imaging techniques. It exhibits specific structural and distribution properties, allowing the differentiation of isomers of various fatty acid chains through refined methods.

1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0-22:6 PE) is a lipid compound utilized in the preparation of liposomes. Liposomes, forming the central component of concentric phospholipid bilayer vesicles, are pivotal in constructing drug delivery systems for anti-cancer and anti-infection applications. They effectively encapsulate hydrophilic payloads within their aqueous internal spaces, while lipophilic compounds are integrated into and become part of the lipid bilayer. This compound is particularly effective for delivering antisense oligonucleotides, addressing challenges such as inefficient cellular uptake and rapid loss in the body.

1,3-Dilinoleoyl-2-docosahexaenoyl glycerol is a triglyceride composed of Linoleic acid at the sn-1 and sn-3 positions, and Docosahexaenoic acid at the sn-2 position.

1,3-Didocosahexaenoyl glycerol (DG(22:6/0:0/22:6)) is an ω-3 polyunsaturated fatty acid that exhibits cardioprotective effects in a rat myocardial ischemia/reperfusion (I/R) injury model through its interaction with Poly-l-glutamic acid (PGA).

(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA ((6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-coenzyme A) acts as an NLRX1 modulator. This compound shows potential for research into immune and metabolism-related diseases.

PySAHA is a versatile HDAC inhibitor that degrades intracellular HDAC through a hydrophobic tagging mechanism. It also exhibits photodynamic therapeutic activity, generating reactive oxygen species upon light exposure. PySAHA inhibits breast cancer cell proliferation and migration while inducing apoptosis (apoptosis). The compound has antitumor properties valuable for breast cancer research.

(S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide (N-Docosahexacnoylethanolamide(22:6)) is a homologue of dehydroepiandrosterone (DHEA). This compound can block Shaker-related voltage-gated potassium channels and inhibits Kv1.2 K+ currents with an IC50 value of 1.5 μM.

4-Iodo-SAHA (1k), an orally active inhibitor of both class I and class II histone deacetylase (HDAC), exhibits EC50 values of 1.1, 0.95, 0.12, 0.24, 0.85, and 1.3 μM for Skbr3, HT29, U937, JA16, and HL60 cell lines, respectively. This compound holds potential for cancer research purposes [1].

Suberoylanilide hydroxamic acid (SAHA) is a class I and class II histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. SAHA-BPyne is a SAHA derivative with a benzophenone crosslinker and an alkyne tag intended to be used for profiling HDAC activities in proteomes and live cells. Such terminal alkyne groups can be used in linking reactions, known as click chemistry, characterized by high dependability and specificity of azide-alkyne bioconjugation reactions. SAHA-BPyne labels HDAC complex proteins both in proteomes at 100 nM and in live cells at 500 nM and demonstrates an IC50 value of ~3 μM for inhibition of HDAC activity in HeLa cell nuclear lysates in an HDAC activity assay.